NASDAQ •
Healthcare •
Biotechnology •
Quote as of 05/11/2026 15:50
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization13.18 mln
Float5.29 mln
Earnings Date05/07/2026
Piotroski F-Score
3
/ 9
Below average
Relative Strength
22
/ 100
Significantly lagging
Debt / Equity
0.02
Debt-free
ROE
-256
Deeply negative
Dividend Yield
0.00%
No dividend
DPS
0.00
No dividend
Business Description
Moleculin Biotech is a Houston-based pharmaceutical company focused on developing treatments for cancer and viral diseases. Its most advanced drug, Annamycin, is currently in clinical trials for certain forms of leukemia and lung tumors. The company is also working on two additional drug families ? one aimed at disrupting the signaling processes that allow brain, pancreatic, and other cancers to grow, and another designed to cut off the energy supply that tumors depend on to survive.
